Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder

VA Palo Alto Health Care System

Status

Not yet enrolling

Conditions

Alcoholism

Alcohol Abuse

Drinking Problem

Drinking Behavior

Alcohol Use Disorder

Treatments

Device: Sham

Device: Active Transcranial Magnetic Simulation

Study type

Interventional

Funder types

Other

Other U.S. Federal agency

NIH

Identifiers

NCT06415721

PADNEW_0003

Details and patient eligibility

About

Alcohol Use Disorders are currently positioned as the third leading cause of preventable death in the United States, constituting a humanitarian crisis with substantial financial burden on society and medical facilities. While several pharmacological interventions exist, 60% of individuals who seek these treatments relapse to alcohol within 6 months. These high relapse rates are due in part to elevated brain response to alcohol cues in the environment. This study seeks to evaluate the efficacy of one session of functional Magnetic Resonance Imaging (fMRI) guided transcranial magnetic stimulation (TMS) as a strategy to reduce brain reactivity to alcohol cues.

Full description

At least 60% of those with AUD will experience a major relapse period within 6 months of treatment, irrespective of the intervention (psychosocial and/or pharmacological) employed. Consequently, the high prevalence of AUD and relapse following treatment in Veterans is associated with substantial resource allocation and costs for the VA Health Care System. Current pharmacological and psychosocial interventions demonstrate only a moderate level of efficacy, which is reflected in the high rate of relapse in AUD. Transcanial Magnetic Stimulation (TMS) is a neurostimulation method that is at the forefront of innovative, non-invasive, and safe treatments for AUD, and other psychiatric disorders. To reduce the high rate of relapse in Veterans with AUD, it is necessary for interventions to more effectively address the associated neurobiological dysfunction. Non-invasive neuromodulation techniques are showing promise toward the aim of modifying specific and selective neural targets related to AUD and relapse. To date, TMS has been primarily delivered to the dorsolateral and medial prefrontal cortices as these regions are, on average, highly reactive to alcohol cues. On an individual basis, however, peak brain response to alcohol cues can vary substantially in spatial location within the brain. Retrospective analyses of TMS-AUD clinical trails has demonstrated that when TMS is delivered to an individual's peak brain response to alcohol cues, the likelihood of remaining abstinent is increased by a factor of 5.6 (relative to sham TMS treatment). This study aims to deliver one session of TMS to a cortical target which displays peak functional connectivity to the ventral striatum, a key brain region mediating reward and alcohol cue reactivity. The ultimate goal of this study evaluate change in brain reactivity to alcohol cues following active and sham TMS.

Enrollment

40 estimated patients

Sex

All

Ages

25 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Between age 25 and 75.
Current DSM-5 diagnosis of moderate to severe AUD (≥4 diagnostic symptoms).
Able to attend scheduled clinic visits
Able to read, understand and voluntarily sign Informed Consent prior to participating in any study-specific procedures or assessments.
If on a medication regimen, that regimen will be stable for the duration of the study;
Fluency in English.

Exclusion criteria

Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, metal in the head, metal in the body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/objected in the head and body within 30 cm of the treatment coil.
General medical condition, disease or neurological disorder that interferes with the assessments or participation.
Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.
Current substance abuse (except caffeine or nicotine) as determined by positive toxicology screen.
Have a mass lesion, cerebral infarct, or other active CNS disease, including an alcohol-related seizure or a seizure disorder. • A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.
Severe impediment to vision, hearing and/or hand movement, likely to interfere with the ability to follow study protocols. • Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).
Taking benzodiazepine or neuroleptic medications, or any medication known to alter seizure threshold
unstable chronic illness.
Current or lifetime history of bipolar disorder or psychosis.
Participation in another concurrent intervention based clinical trial.